ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

1. Investment: ITM Isotope Technologies Munich SE (ITM) has secured a €188 million equity investment led by Temasek, with participation from funds managed by BlackRock, Qatar Investment Authority (QIA), ATHOS, and Carbyne.
2. Radiopharmaceutical Pipeline: The investment will be used to advance and expand ITM's innovative radiopharmaceutical pipeline, including the phase III lead candidate, ITM-11 (n.c.a. 177Lu-edotreotide), for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
3. Medical Radioisotope Manufacturing: ITM will utilize the funds to increase its in-house manufacturing capacities for Lutetium-177 (177Lu) and expand them to new, high-value medical radioisotopes, including Actinium-225 (225Ac).
4. Global Supply Network: The company will provide these sought-after medical radioisotopes to its global supply network and apply them to broaden its Radiopharmaceutical Therapy (RPT) pipeline, designed to address various hard-to-treat cancer indications.
5. Industry Position: ITM is a leading radiopharmaceutical biotech company dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors.